Vivian Paintsil

Vivian Paintsil

Auto-generated profile, based on publicly available information

Vivian Paintsil

Pediatric Oncology Unit, Child Health Directorate Komfo Anokye Teaching Hospital Kumasi Ghana

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 October 2021 in Nature Reviews Disease Primers
Verified
Journal Article
Open access
PDF file
FSFilippo Spreafico
Filippo Spreafico
CFConrad V. Fernandez
Conrad V. Fernandez
JBJesper Brok
Jesper Brok
KNKayo Nakata
Kayo Nakata
GVGordan Vujanic
Gordan Vujanic
KPKathy Pritchard-Jones
Kathy Pritchard-Jones
Wilms tumour (WT) is a childhood embryonal tumour that is paradigmatic of the intersection between disrupted organogenesis and tumorigenesis. Many WT genes play a critical (non-redundant) role in early nephrogenesis. Improving patient outcomes requires advances in understanding and targeting of the multiple genes and cellular control pathways now identified as active in WT development. Decades of clinical and basic research have helped to gradually optimize clinical care. Curative therapy is achievable in 90% of affected children, even those with disseminated disease, yet survival disparities within and between countries exist and deserve commitment to change. Updated epidemiological studies have also provided novel insights into global incidence variations. Introduction of biology-driven approaches to risk stratification and new drug development has been slower in WT than in other childhood tumours. Current prognostic classification for children with WT is grounded in clinical and pathological findings and in dedicated protocols on molecular alterations. Treatment includes conventional cytotoxic chemotherapy and surgery, and radiation therapy in some cases. Advanced imaging to capture tumour composition, optimizing irradiation techniques to reduce target volumes, and evaluation of newer surgical procedures are key areas for future research.

24 February 2022 in Frontiers in Genetics
Verified
Journal Article
Open access
VPVivian Paintsil
Vivian Paintsil
EAEvans Xorse Amuzu
Evans Xorse Amuzu
INIsaac Nyanor
Isaac Nyanor
EAEmmanuel Asafo-Adjei
Emmanuel Asafo-Adjei
AMAbdul Razak Mohammed
Abdul Razak Mohammed
TCthe Sickle Cell Disease in Sub-Saharan Africa Consortium
the Sickle Cell Disease in Sub-Saharan Africa Consortium
Sickle cell disease (SCD) is the most common clinically significant hemoglobinopathy, characterized by painful episodes, anemia, high risk of infection, and other acute and chronic complications. In Africa, where the disease is most prevalent, large longitudinal data on patients and their outcomes are lacking. This article describes the experiences of the Kumasi Center for SCD at the Komfo Anokye Teaching Hospital (KCSCD-KATH), a Sickle Pan-African Research Consortium (SPARCO) site and a SickleInAfrica Consortium member, in establishing a SCD registry for the evaluation of the outcomes of patients. It also provides a report of a preliminary analysis of the data. The process of developing the registry database involved comprehensive review of the center’s SCD patient medical records, incorporating data elements developed by the SickleInAfrica Consortium and obtaining ethical clearance from the local Institutional Review Board. From December 2017 to March 2020, 3,148 SCD patients were enrolled into the SCD registry. Enrollment was during the SCD outpatient clinic visits or through home visits. A significant proportion of the patients was from the newborn screening cohort (50.3%) and was males (52.9%). SCD-SS, SCD-SC, and Sβ +thalassemia were seen in 67.2, 32.5, and 0.3% patients, respectively. The majority of the patients were in a steady state at enrollment; however, some were enrolled after discharge for an acute illness admission. The top two clinical diagnoses for SCD-SS patients were sickle cell painful events and acute anemia secondary to hyperhemolysis with incidence rates of 141.86 per 10,000 person months of observation (PMO) and 32.74 per 10,000 PMO, respectively. In SCD-SC patients, the top two diagnoses were sickle cell painful events and avascular necrosis with incidence rates of 203.09 per 10,000 PMO and 21.19 per 10,000 PMO, respectively. The SPARCO Kumasi site has developed skills and infrastructure to design, manage, and analyze data in the SCD registry. The newborn screening program and alternative recruitment methods such as radio announcement and home visits for defaulting patients were the key steps taken in enrolling patients into the registry. The registry will provide longitudinal data that will help improve knowledge of SCD in Ghana and Africa through research.

12 January 2023 in Frontiers in Genetics
Verified
Journal Article
Open access
VPVivian Paintsil
Vivian Paintsil
MAMwashungi Ally
Mwashungi Ally
HIHezekiah Isa
Hezekiah Isa
KAKofi A. Anie
Kofi A. Anie
JMJosephine Mgaya
Josephine Mgaya
KOKwaku Ohene-Frempong
Kwaku Ohene-Frempong
Introduction:Sickle Cell Disease (SCD) causes significant morbidity and mortality particularly in sub-Saharan Africa (SSA) where it contributes to early childhood deaths. There is need to standardize treatment guidelines to help improve overall SCD patient health outcomes. We set out to review existing guidelines on SCD and to set minimum standards for management of SCD for the different referral levels of healthcare.Methods:A standards of care working group (SoC-WG) was established to develop the SoC recommendations. About 15 available SCD management guidelines and protocols were reviewed and themes extracted from them. The first draft was on chosen themes with 64 major headings and subtopics. Using a summarised WHO levels of referral document, we were able to get six different referral levels of healthcare. The highest referral level was the tertiary facilities whilst the lowest level was the home setting. Recommendations for SCD management for the regional, district, sub-districts, health posts and CHPs compounds were also drafted.Results:The results from this review yielded a guidelines document which had recommendations for management of SCD on 64 topics and subtopic for all the six (6) different referral levels.Discussions:Every child with SCD need to receive comprehensive care that is coordinated at each level. This recommendation is unique in terms of the availability of recommendations for different levels of care as compared to the traditional guidelines which is more focused at the tertiary levels. Patients can access care at any of the other lower referral hospitals and be managed with recommendations that are in keeping with institutional resources at that level. When such patients need care that requires expertise that is not available at that level, the recommendations will be to refer to the appropriate referral level where those expertise are available. This encourages patients to have good clinical care nearer their homes but also having access to specialist screening modalities and expertise at the tertiary hospitals if need be. With this, patient are not limited to a specific referral level when interventions cannot be instituted for them.Conclusion:This SoC recommendations document is a useful material that can be used for consistent standards of treatment in SSA.

11 November 2022 in Pediatric Hematology and Oncology
Verified
Journal Article
Closed access
JHJaques Van Heerden
Jaques Van Heerden
JBJoyce Balagadde-Kambugu
Joyce Balagadde-Kambugu
RARacheal Angom
Racheal Angom
RLRebecca Claire Lusobya
Rebecca Claire Lusobya
GCGuillermo L Chantada
Guillermo L Chantada
JGJennifer A. Geel
Jennifer A. Geel
Limited survival data for the six Global Initiative for Childhood Cancer (GICC) priority cancers are available in Africa. Management of pediatric malignancies in Africa is challenging due to lack of resources, setting-specific comorbidities, high rates of late presentation and treatment abandonment. Reporting of outcome data is problematic due to the lack of registries. With the aim of evaluating the feasibility of baseline outcomes for the six index cancers, we present a descriptive analysis of respective survival rates in Africa. The survival rates were between 18% (lower middle-income countries) to 82.3% (upper middle-income countries) for acute lymphoblastic leukemia, between 26.9% (low-income countries) to 77.9% (upper middle-income countries) for nephroblastoma, between 23% (low-income countries) to 100% (upper middle-income countries), for retinoblastoma, 45% (low-income countries) to 95% (upper middle-income countries) for Hodgkin lymphoma and 28% (low-income countries) to 76% (upper middle-income countries) for Burkitt lymphoma. Solutions to improve survival rates and reported outcomes include establishing and funding sustainable registries, training and to actively include all countries in consortia from different African regions.

18 June 2025 in Communications Medicine
Verified
Journal Article
Open access
PDF file
EAEvans Xorse Amuzu
Evans Xorse Amuzu
FUFlorence Urio
Florence Urio
EDElliot Eli Dogbe
Elliot Eli Dogbe
PPPeter Ponsian
Peter Ponsian
SASuraj Yawnumah Abubakar
Suraj Yawnumah Abubakar
SNSiana Nkya
Siana Nkya
Background Prevalence of sickle cell disease (SCD) across African countries ranges between 1–3% and contributes up to 7–16% of under-five mortality. In order to bridge the gap in management and cognate research, the SickleInAfrica consortium was established in 2017 to facilitate collaboration among African nations in order to establish regionally relevant healthcare standards for SCD patients. This work utilised the SickleInAfrica platform to study the levels of HbF and F cells and their relationship with sickle cell disease clinical manifestations in Ghana, Nigeria and Tanzania. Methods This study enrolled 290 individuals with SCD aged five years and above who were confirmed to be at steady state and were hydroxyurea naïve. Clinical history was obtained using an interviewer-administered questionnaire. Haematological parameters were determined by an automated haematology analyser, while quantification of HbF and F cells was implemented by high-performance liquid chromatography and flow cytometry, respectively. Age-adjusted logistic regression was employed to assess the association of HbF with the clinical manifestations. Results The most reported complication of SCD, requiring management in a hospital setting is pain crises, ranging from 66–96% with the highest in Tanzania and lowest in Ghana. HbF and F cell parameters show significant association with transfusion rates, frequency of painful crises and episodes of febrile illness. Conclusion This work highlights important differences and similarities across SCD populations in the three countries. This is important especially in development of interventions in the light of personalised medicine.

29 February 2024 in JFO Open Ophthalmology
Verified
Journal Article
Open access
VEVera A. Essuman
Vera A. Essuman
BABENJAMIN ABAIDOO
BENJAMIN ABAIDOO
KAKwesi Amissah-Arthur
Kwesi Amissah-Arthur
VBV.M Beyuo
V.M Beyuo
ANA. Nimako
A. Nimako
HDHelen Dimaras
Helen Dimaras
Purpose: To examine the determinants of retinoblastoma treatment delay in children diagnosed with retinoblastoma in Ghana. Methods: : The study is a retrospective cross-sectional review of hospital records of children with retinoblastoma from treatment centers in Ghana from 2014 to 2019. Data were collected by trained ophthalmology residents and nurses and entered into a REDCap (Research Electronic Data Capture) database. Frequencies and proportions were used in describing categorical variables. Independent samples t‑test and the Mann-Whitney U test were used to compare equality of means and median values. P-values less than 0.05 were considered statistically significant. Results: Of the 234 children, 224 (95.7%) were referred cases and the remaining 10 (4.3%) were walk-ins. The average distance traveled by the children from home to retinoblastoma treatment center was 118.9 ± 128.4 km. The mean parental lag time was 7.6 ± 4.6 months. Longer parental lag time was associated with older age at presentation and unilateral disease (p < 0.05). The mean referral lag time was 0.6 ± 0.5 months. Longer referral lag time was associated with patients who abandoned treatment or died compared with those who survived at last follow-up (p = 0.036). A total of 125 (55.8%) cases abandoned treatment after being referred and seen at a treatment center. Conclusion: Analysis of the pathway from the observance of the first sign of retinoblastoma to presentation to a health facility reveals a need to reduce both parental and referral lag times in order to improve retinoblastoma outcomes. Future studies may help to unravel factors contributing to long parental lag time, referral lag time and abandonment of treatment in Ghana.